Themes / Group
Building · established relationshipLatest completed snapshot · Aug 20 · 16:27 ET

MARKET-DISCOVERED GROUP

Biotechnology Therapeutics

THE TRADER READShared activity without a clean directional read

0 of 10 measured SPY-adjusted paths align to the mixed across 5.6 effective names. Common-bar coverage spans 10 of 13 cohort members. Capital-flow agreement is 30%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth2 up · 9 down-0.0% median path versus SPY
Capital-flow alignment30%Price breadth is not yet confirmed by flow
Activity nowHotActivity score 85/100 · lift 1.3×
Evidence depth2 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 10:15–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceMDGL registered the first material upside path

    +3.32% session path at the threshold · MDGL

  2. 5-minute inferenceSRRK registered a material downside path

    -2.55% session path at the threshold · SRRK

  3. 5-minute inferencePTGX registered a material downside path

    -1.97% session path at the threshold · PTGX

  4. 5-minute inferenceGMAB registered a material downside path

    -1.02% session path at the threshold · GMAB

2 earlier filing context receipts

TUE, FEB 24ADMA filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

SUN, MAR 1APGE filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

SPY-adjusted 5m paths

Observed movement is broad across 5.6 effective names. MDGL represents 25.0% of absolute path energy; 0 of 10 members align without a clean common direction.

ConstructionBroad25.0% from the largest path
Effective names5.6 / 1010 of 13 cohort members had common bars
Direction breadthMixedmixed relative path · 0 counter-moving
Largest moverMDGL 25.0%49.4% from the top two paths
MDGL25.0%Independent direction · path +2.85% · basket +0.28pp
SRRK24.4%Independent direction · path -2.79% · basket -0.28pp
PTGX17.0%Independent direction · path -1.94% · basket -0.19pp
GMAB11.2%Independent direction · path -1.28% · basket -0.13pp
ASND10.9%Independent direction · path -1.25% · basket -0.13pp
ADMA3.7%Independent direction · path +0.43% · basket +0.04pp
KNSA3.1%Independent direction · path +0.35% · basket +0.04pp
ARGX2.2%Independent direction · path +0.26% · basket +0.03pp
PCVX1.4%Independent direction · path -0.16% · basket -0.02pp
IONS1.1%Flat / inactive path · path +0.13% · basket +0.01pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. MDGL moved higher firstFirst member to clear the material path threshold · path +3.32%
  2. SRRK registered a material lower path0m after the first price move · path -2.55%
  3. PTGX registered a material lower path0m after the first price move · path -1.97%
  4. GMAB registered a material lower path0m after the first price move · path -1.02%
  5. ASND registered a material lower path0m after the first price move · path -0.54%
  6. KNSA registered a material higher path0m after the first price move · path +0.62%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

SPY-adjusted
Sep 9 · 10:15 ET15:50 ETSep 9 · 15:55 ET
Group median -0.01%Strongest relative path MDGLWeakest relative path SRRK

Observed member paths adjusted against SPY. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

10/13 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across APGE, CRNX, KNSA, MDGL, PCVX, PTGX, SRRK, TARS.

product pipeline / R&D affecting expense

“The increase of $46.8 million was primarily driven by further development of our zumilokibart (APG777) program, increases in personnel costs and equity-based compensation, associated with the growth in our research and development team, and increases in external-discovery related costs and other expenses, partially offset by decreases in expenses related to our APG990/APG279, APG333/APG273 and APG808 programs.”

APGE 10-K · 2026-03-02
credit / rates affecting expense

“Loss on Extinguishment of Debt As a result of the repayment of all obligations outstanding under the Ares Credit Facility (as defined in Liquidity and Capital Resources below), we have incurred prepayment penalties and wrote off the remaining unamortized debt issuance costs and discount associated with that facility, which resulted in recognition of debt extinguishment losses of $2.2 million during the three months ended September 30, 2025.”

ADMA 10-Q · 2025-11-05
credit / rates affecting interest expense

“Other Income, Net Other income, net increased $3.1 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily related to interest income earned on our cash, cash equivalents and marketable securities, partially offset by non-cash interest expense associated with our Revenue Share Agreement entered into during the second quarter of 2026.”

APGE 10-Q · 2026-08-10
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

BMRNNot confirming

SRRK · text peer

NBIXNot confirming

CRNX · text peer

ROIVNot confirming

PTGX · text peer

HRMYNot confirming

CRNX · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
APGECRNXPCVXSRRKTARSASNDPTGXADMAMDGLGMABKNSAARGXIONS

8/13 active2 rising · 10 falling · 1 flat

MemberUnusual activityToday's moveRead now
APGEApogee Therapeutics, Inc.
Most unusual · 100/100
-0.0%
Active; unclassifiedActive in 47.4% of observed group sessions
CRNXCrinetics Pharmaceuticals, Inc.
Elevated · 83/100
+0.0%
Active; unclassifiedActive in 15.8% of observed group sessions
PCVXVaxcyte, Inc.
Elevated · 19/100
-1.4%
Active; unclassifiedActive in 36.8% of observed group sessions
SRRKScholar Rock Holding Corporation
Elevated · 18/100
-4.7%
Active; unclassifiedActive in 26.3% of observed group sessions
TARSTarsus Pharmaceuticals, Inc.
Participating · 17/100
-5.1%
Flow confirmerActive in 57.9% of observed group sessions
ASNDAscendis Pharma A/S
Participating · 17/100
-3.5%
Active; unclassifiedActive in 26.3% of observed group sessions
PTGXProtagonist Therapeutics, Inc.
Participating · 14/100
-0.7%
Active; unclassifiedActive in 57.9% of observed group sessions
ADMAADMA Biologics, Inc.
Participating · 13/100
-0.8%
Active; unclassifiedActive in 10.5% of observed group sessions
MDGLMadrigal Pharmaceuticals, Inc.
Participating · 13/100
+2.3%
First material pathActive in 21.1% of observed group sessions
GMABGenmab A/S
Quiet · 9/100
-1.5%
Watch / laggardActive in 15.8% of observed group sessions
KNSAKiniksa Pharmaceuticals International, plc
Quiet · 9/100
+1.7%
Watch / laggardActive in 10.5% of observed group sessions
ARGXargenx SE
Quiet · 7/100
-0.5%
Watch / laggardActive in 10.5% of observed group sessions
IONSIonis Pharmaceuticals, Inc.
Quiet · 6/100
-1.3%
Watch / laggardActive in 0% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
APGEApogee Therapeutics, Inc.Most unusual-0.0%47.4% of 19 sessionsMost unusual activity in this snapshot; performance direction may differ.
CRNXCrinetics Pharmaceuticals, Inc.Participating+0.0%15.8% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
PCVXVaxcyte, Inc.Participating-1.4%36.8% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
SRRKScholar Rock Holding CorporationParticipating-4.7%26.3% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
TARSTarsus Pharmaceuticals, Inc.Participating-5.1%57.9% of 19 sessionsPrice participation with accumulating signed flow.
ASNDAscendis Pharma A/SParticipating-3.5%26.3% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
PTGXProtagonist Therapeutics, Inc.Participating-0.7%57.9% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
ADMAADMA Biologics, Inc.Participating-0.8%10.5% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
MDGLMadrigal Pharmaceuticals, Inc.Participating+2.3%21.1% of 19 sessionsPrice participation with accumulating signed flow.
GMABGenmab A/SQuiet / lagging-1.5%15.8% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
KNSAKiniksa Pharmaceuticals International, plcQuiet / lagging+1.7%10.5% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
ARGXargenx SEQuiet / lagging-0.5%10.5% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
IONSIonis Pharmaceuticals, Inc.Quiet / lagging-1.3%0% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Observed follow-through

5/5 events completed
30 minutes+0.26%100% continuation · n=3Median MFE +0.71% · MAE -0.19%
60 minutes+0.28%100% continuation · n=3Median MFE +0.71% · MAE -0.19%
Session close+0.03%50% continuation · n=2Median MFE +0.63% · MAE -0.56%
Next-session close+0.28%67% continuation · n=3Median MFE +0.71% · MAE -0.19%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 2 completed episodes across 19 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support26 daysHow often the cohort identity was observed
Completed episodes2Separate periods of broad group activity
Active sessions19Completed session observations, not trades
2026-07-28 → 2026-08-2012 active sessionsNo name was active through every recorded session
2026-07-13 → 2026-07-237 active sessions6.7% composition consistency through the episode
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
PTGX57.9% · 2 episodes
TARS57.9% · 2 episodes
APGE47.4% · 1 episode
PCVX36.8% · 2 episodes
ASND26.3% · 1 episode
SRRK26.3% · 1 episode
MDGL21.1% · 2 episodes
CRNX15.8% · 1 episode
GMAB15.8% · 2 episodes
ADMA10.5% · 1 episode
ARGX10.5% · 1 episode
KNSA10.5% · 2 episodes
IONS0% · 0 episodes